Long Noncoding RNA LINC02249 Is a Prognostic Biomarker and Correlates with Immunosuppressive Microenvironment in Skin Cutaneous Melanoma

Overview

Journal J Oncol

Specialty Oncology

Date 2022 Sep 19

PMID 36117849

Authors

Maotao Du

Liang Han

Pan Shen

Dengyan Wu

Shenghao Tu

Affiliations

Soon will be listed here.

Abstract

Skin cutaneous melanoma (SKCM) is one of the most aggressive and life-threatening tumors. It has a high incidence rate, as well as significant metastasis and fatality rates. To successfully treat SKCM and to increase the overall survival rate, early identification and risk stratification are both absolutely necessary. Long noncoding RNAs (lncRNAs) play a significant regulatory role in a variety of cancers. However, the expression and function of many lncRNAs have not been investigated. We evaluated the expression profile of the long noncoding RNA LINC02249 (LINC02249) in pan-cancers by using data on gene expression obtained from TCGA and GTEx. The biological function of LINC02249 was determined by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). The prognostic value of LINC02249 expression in SKCM patients was statistically analyzed. Besides, the ssGSEA approach was utilized in order to investigate the degree to which LINC02249 expression is correlated with tumor immune infiltration. In this study, the expression of LINC02249 was found to be abnormally high in a variety of tumors, according to our findings. When compared with nontumor specimens, the level of expression of LINC02249 was shown to be significantly elevated in SKCM samples. GO and KEGG assays revealed LINC02249 may be involved in tumor progression. High expression of LINC02249 was associated with shorter overall survival and disease-specific survival of SKCM patients. More importantly, multivariate methods revealed that LINC02249 expression was an independent prognostic factor for SKCM cases. Using ssGSEA, we found that the expression of LINC02249 was negatively associated with different tumor-infiltrating immune cells, especially aDC, Treg, and macrophages. Overall, our findings suggested that LINC02249 can serve as a novel biomarker to predict the prognosis and immune infiltration in SKCM.

Citing Articles

Knowledge graph and frontier trends in melanoma-associated ncRNAs: a bibliometric analysis from 2006 to 2023.

Wang R, Zhu X, Wang Y Front Oncol. 2024; 14:1439324.

PMID: 39659781 PMC: 11628868. DOI: 10.3389/fonc.2024.1439324.

Integration of single-cell and bulk RNA sequencing data reveals that CYTOR is a potential prognostic and immunotherapeutic response marker for skin cutaneous melanoma.

Zhang M, Ju Y, Xue L, Zhao X, Xu X, Wu G J Cancer. 2024; 15(12):3890-3902.

PMID: 38911384 PMC: 11190755. DOI: 10.7150/jca.94823.

Regulatory miRNAs and lncRNAs in Skin Cancer: A Narrative Review.

Natarelli N, Boby A, Aflatooni S, Tran J, Diaz M, Taneja K Life (Basel). 2023; 13(8).

PMID: 37629553 PMC: 10455148. DOI: 10.3390/life13081696.

Genomics and Epigenomics in the Molecular Biology of Melanoma-A Prerequisite for Biomarkers Studies.

Zob D, Augustin I, Caba L, Panzaru M, Popa S, Popa A Int J Mol Sci. 2023; 24(1).

PMID: 36614156 PMC: 9821083. DOI: 10.3390/ijms24010716.

The role of lncRNAs in the tumor microenvironment and immunotherapy of melanoma.

Zhou W, Xu X, Cen Y, Chen J Front Immunol. 2023; 13:1085766.

PMID: 36601121 PMC: 9806239. DOI: 10.3389/fimmu.2022.1085766.

References

Wohlmuth C, Wohlmuth-Wieser I . Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. Am J Clin Dermatol. 2021; 22(5):639-651. PMC: 8421300. DOI: 10.1007/s40257-021-00614-7. View

Zhang Y, Tao Y, Liao Q . Long noncoding RNA: a crosslink in biological regulatory network. Brief Bioinform. 2017; 19(5):930-945. DOI: 10.1093/bib/bbx042. View

Zheng Q, Zhang Q, Yu X, He Y, Guo W . FENDRR: A pivotal, cancer-related, long non-coding RNA. Biomed Pharmacother. 2021; 137:111390. DOI: 10.1016/j.biopha.2021.111390. View

Gowthaman U, Garcia-Pichardo D, Jin Y, Schwarz I, Marquardt S . DNA Processing in the Context of Noncoding Transcription. Trends Biochem Sci. 2020; 45(12):1009-1021. DOI: 10.1016/j.tibs.2020.07.009. View

Kim J, Piao H, Kim B, Yao F, Han Z, Wang Y . Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018; 50(12):1705-1715. PMC: 6265076. DOI: 10.1038/s41588-018-0252-3. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Stevens G, McKay M . Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncol. 2006; 7(7):575-83. DOI: 10.1016/S1470-2045(06)70758-6. View

Hao T, Wang Z, Yang J, Zhang Y, Shang Y, Sun J . MALAT1 knockdown inhibits prostate cancer progression by regulating miR-140/BIRC6 axis. Biomed Pharmacother. 2020; 123:109666. DOI: 10.1016/j.biopha.2019.109666. View

Merkel E, Mohan L, Shi K, Panah E, Zhang B, Gerami P . Paediatric melanoma: clinical update, genetic basis, and advances in diagnosis. Lancet Child Adolesc Health. 2019; 3(9):646-654. DOI: 10.1016/S2352-4642(19)30116-6. View

10.

Li F, Li X, Qiao L, Liu W, Xu C, Wang X . MALAT1 regulates miR-34a expression in melanoma cells. Cell Death Dis. 2019; 10(6):389. PMC: 6525244. DOI: 10.1038/s41419-019-1620-3. View

11.

Okla K, Farber D, Zou W . Tissue-resident memory T cells in tumor immunity and immunotherapy. J Exp Med. 2021; 218(4). PMC: 7992502. DOI: 10.1084/jem.20201605. View

12.

McLaughlin M, Patin E, Pedersen M, Wilkins A, Dillon M, Melcher A . Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020; 20(4):203-217. DOI: 10.1038/s41568-020-0246-1. View

13.

Kamposioras K, Pentheroudakis G, Pectasides D, Pavlidis N . Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol. 2010; 78(2):112-26. DOI: 10.1016/j.critrevonc.2010.04.007. View

14.

Ho V, Sober A . Therapy for cutaneous melanoma: an update. J Am Acad Dermatol. 1990; 22(2 Pt 1):159-76. DOI: 10.1016/0190-9622(90)70019-e. View

15.

Chen Y, Teer J, Eroglu Z, Wu J, Koomen J, Karreth F . Translational pathology, genomics and the development of systemic therapies for acral melanoma. Semin Cancer Biol. 2019; 61:149-157. PMC: 7771370. DOI: 10.1016/j.semcancer.2019.10.017. View

16.

Terheyden P, Krackhardt A, Eigentler T . The Systemic Treatment of Melanoma. Dtsch Arztebl Int. 2019; 116(29-30):497-504. PMC: 6726851. DOI: 10.3238/arztebl.2019.0497. View

17.

Marzagalli M, Ebelt N, Manuel E . Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol. 2019; 59:236-250. DOI: 10.1016/j.semcancer.2019.08.002. View

18.

Gogas H, Eggermont A, Hauschild A, Hersey P, Mohr P, Schadendorf D . Biomarkers in melanoma. Ann Oncol. 2009; 20 Suppl 6:vi8-13. PMC: 2712589. DOI: 10.1093/annonc/mdp251. View

19.

Wang Y, Li D, Lu J, Chen L, Zhang S, Qi W . Long noncoding RNA TTN-AS1 facilitates tumorigenesis and metastasis by maintaining TTN expression in skin cutaneous melanoma. Cell Death Dis. 2020; 11(8):664. PMC: 7441063. DOI: 10.1038/s41419-020-02895-y. View

20.

Tanaka A, Sakaguchi S . Regulatory T cells in cancer immunotherapy. Cell Res. 2016; 27(1):109-118. PMC: 5223231. DOI: 10.1038/cr.2016.151. View